Ontology highlight
ABSTRACT:
SUBMITTER: El-Amm J
PROVIDER: S-EPMC3813614 | biostudies-literature | 2013 Aug
REPOSITORIES: biostudies-literature
El-Amm Joelle J Patel Nihar N Freeman Ashley A Aragon-Ching Jeanny B JB
Clinical Medicine Insights. Oncology 20130821
Enzalutamide, previously known as MDV300, is an oral, second-generation androgen receptor (AR) signaling inhibitor or antagonist that was approved by the Food and Drug Administration in 2012 for the treatment of metastatic castrate-resistant prostate cancer (mCRPC) postdocetaxel. Preclinical studies have demonstrated impressive affinity to the AR compared to the first-generation AR inhibitors. The landmark Phase III AFFIRM trial demonstrated improved overall survival benefit compared to placebo ...[more]